Saturday 17 October 2026
Export NCEL’s income statement to Excel — free account
NewcelX Ltd.
NCEL Healthcare Biotechnology
Insiders bought in the last twelve months.
2.50
0.35
−12.28%
Follow NCEL
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 440.00 | 132.00 | 104.00 | 17.30 | 1.89 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 2,940.00 | 960.00 | 752.00 | 240.00 | 33.70 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 4 | 6 | 6 | 2 | 4 | 3 | 4 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (5) | (5) | (3) | (12) | (16) | (12) | (7) | (8) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (5) | (5) | (3) | (12) | (16) | (12) | (7) | (8) | |||||
| Depreciation | — | — | — | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.46) | (318.55) | (164.00) | (400.00) | (336.00) | (128.00) | (2.43) | (2.16) | |||||
| Cash flow | — | — | (0.25) | (11.11) | (41.92) | (501.21) | (282.10) | (101.51) | (0.36) | (0.72) | |||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | (1.33) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | (0.25) | (11.11) | (41.92) | (502.54) | (282.10) | (101.51) | (0.36) | (0.72) | |||||
| Book value | — | — | (0.79) | (360.88) | (516.33) | 18.20 | 66.68 | (92.60) | (2.70) | 1.89 | |||||
| Shares, m | — | — | 11 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (3) | 0 | (1) | (15) | (14) | (10) | (1) | (3) | ||||
| Capex | — | — | — | — | — | 0 | — | — | 0 | 0 | |||||
| Free cash flow | — | — | (3) | 0 | (1) | (15) | (14) | (10) | (1) | (3) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | (2) | (4) | (7) | 3 | 6 | (6) | (8) | (1) | ||||
| Total debt | — | — | 7 | 0 | 1 | — | — | 2 | 8 | 0 | |||||
| Net debt | — | — | 7 | 0 | 1 | (5) | (9) | 1 | 7 | (2) | |||||
| Shareholders’ equity | — | — | (9) | (6) | (9) | 1 | 3 | (9) | (8) | 7 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (7,069.78) | (1,293.85) | (299.94) | (342.48) | (219.34) | (218.86) | (523.49) | (134.43) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (29.63) | |||||
| ROE | — | — | 68.69 | 72.70 | 37.76 | 283.03 | (862.93) | 438.41 | 85.53 | 2,225.20 | |||||
Negative figures in brackets.
Charts ten years each
NewcelX Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PBM Psyence Biomedical Ltd. | $16.5M | 0.2× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| TCRX TScan Therapeutics, Inc. | $16.2M | — (loss-making) | — (loss-making) | −65.83% (below 0%: shrinking) | n/m | +18.95% (above 0%: growing) | 100.00% | (2,901.33%) | Compare |
| AKTX Akari Therapeutics PLC | $15.5M | — (loss-making) | — | — | n/m | +4.51% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $15.3M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | |
| MRKR MARKER THERAPEUTICS, INC. | $15.3M | — (loss-making) | — (loss-making) | +2.75% (above 0%: growing) | n/m | −97.84% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GTBP GT Biopharma, Inc. | $15.2M | — (loss-making) | — | −100.00% (below 0%: shrinking) | n/m | −41.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DARE Dare Bioscience, Inc. | $14.6M | — (loss-making) | — (loss-making) | +984.43% (above 0%: growing) | n/m | −30.23% (below 0%: shrinking) | (70.56%) | (1,582.93%) | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | Compare |
| Median of peers | $15.4M | — | — | −77.58% | — | −35.78% | 0.00% | 0.00% |
NewcelX Ltd. (NCEL) key facts
- NewcelX Ltd. (NCEL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, NCEL traded at $2.50, a market capitalization of $15.3 million.
- Return on equity was 2,225.2% and debt-to-equity 0.06.
NewcelX Ltd. (NCEL) Latest News
No news at this impact. Lower the threshold for more.